Lung cancer is the second most common cancer in both men and women and non-small cell lung cancer (NSCLC) accounts for more than 86% of all lung cancers (1). Lung cancer survivors are a growing yet understudied patient population. Even with the high mortality associated with lung cancer, the number of lung cancer patients added to the survivor population every year is significantly high due to high lung cancer incidence rates (224,210 new cases diagnosed annually) (1). Approximately 26,000 individuals become long-term lung cancer survivors annually (2). There are approximately 526,510 lung cancer survivors in the US as of January 2016, and this number is expected to rise to 673,370 by 2026 (1). Beyond this estimate, the number of survivors will likely increase further with the implementation of lung cancer screening in smokers that can detect patients with early-stage (stage I and II) NSCLC. The majority of the lung cancer survivors are patients with early-stage NSCLC who are treated with surgery. These patients have a significant risk of mortality as the 5-year survival for early-stage NSCLC is only 55.6% (3). These poor survival rates are primarily because lung cancer survivors have a significantly higher risk for developing another lung cancer; either a new cancer (1–2% per-year risk) or recurrent disease (10–38% overall risk) (4,5). They are also at higher risk for other cancers such as cancers of the larynx, colon, esophagus and stomach with the estimated risk being 3–6% per year (6).

Due to the high mortality in lung cancer survivors, early detection and treatment of both recurrence and second cancers in these patients is paramount to improved outcomes. A study in 1,294 patients with lung cancer found a 20% recurrence rate and a 7% rate for second primary cancers with median follow-up of 35 months from diagnosis. Approximately 93% of second cancers and 61% of recurrences were identified by surveillance scans (7). Early identification of recurrence or a second cancer through surveillance may improve survival. In a prospective study in 192 lung cancer survivors, the 3-year survival was improved in the 36 patients whose asymptomatic recurrence was identified by surveillance (31%) compared to 13% in all patients (8). In a retrospective analysis using SEER-Medicare linked database in 10,680 patients with early-stage NSCLC treated with surgical resection, survivors who received regular imaging experienced improved survival compared to survivors who did not (9). While there is evidence to support regular surveillance, there is no consensus on the optimal frequency and timing of surveillance after curative resection of lung cancer. Clinical guidelines from the National Comprehensive Cancer Network (NCCN) as well as the European Society for Medical Oncology (ESMO) recommend CT scans every 6 months for first 2–3 years after lung cancer resection and yearly CT scans thereafter (10,11). However, these clinical guidelines are consensus-based and not evidence-based as there is not enough data to define the optimal strategy for surveillance in these patients.
In 2018, McMurry et al. reported results from a retrospective analysis of the National Cancer Database (NCDB) that investigated the association between intensity of surveillance and survival following surgical resection for NSCLC (12). This study randomly selected patients who were diagnosed with Stage I to III NSCLC between 2006 and 2007 and underwent surgical resection. A total of 4,463 patients were included and grouped into three surveillance groups based on time from surgery to first surveillance using CT scan (3-, 6-month and annual). Patients were followed from the time of surgery through December 2012 or until first recurrence, new second cancer or death. Analysis was restricted to patients who remained disease free through 14 months postoperatively (n=3,552). Approximately 11.0% of these patients developed a new second cancer and 23.8% developed a recurrence during the follow-up period. There was no difference in these rates between the surveillance groups (P value =0.49). In this cohort, more frequent surveillance was not associated with longer risk-adjusted overall survival. The hazard ratio (HR) for 6-month follow-up relative to 3 months was 1.16 [95% confidence interval (CI): 0.99 to 1.36], whereas the HR for yearly surveillance compared to 3 months was 1.06 (95% CI: 0.86 to 1.31). The authors concluded that more frequent surveillance after lung cancer surgery is not associated with improved survival.

The study by McMurry et al. (12) described above has a number of notable strengths. The analysis utilized a unique dataset through a Commission on Cancer (CoC) special study mechanism that augmented data from NCDB. This CoC initiative was part of a quality improvement effort so that there is better documentation of comorbidity and recurrence of NCDB data and as a result, this study had access to data on recurrence abstracted by registry staff from the patient records. The dataset is also representative of the general population as NCDB captures data from about 70% newly diagnosed cancer cases from more than 1,500 hospitals in the United States (13). Also, only 4% patients had missing information about treatment or comorbidities. However, the main limitation of this study is the retrospective nature and inclusion of patients with stage III NSCLC. The only variable that was significantly different between the three surveillance groups was the stage of NSCLC. The frequent surveillance (3-month) group had more patients with stage III disease (18.7% vs. 15%) and fewer patients with stage I disease (60% vs. 65%) compared to the 6-month and annual surveillance groups. As patients with more advanced stage have worse survival, this may have introduced bias in the results. It would have been interesting to see the impact on the study findings if the analysis was stratified by stage. A retrospective study using SEER-Medicare merged dataset reported that receipt of surveillance scan between 4 to 8 months after surgery in patients with NSCLC was associated with improved survival in stage I NSCLC (HR: 0.85; 95% CI: 0.74 to 0.98), but not in stage II (HR: 1.01; 95% CI: 0.71 to 1.42) (14).

The frequency of surveillance in early-stage NSCLC survivors is an important question which warrants a prospective study. Any retrospective analysis looking at this question (including the study by McMurry et al.) will be complicated by two factors: selection bias due to excluding patients who recur or are lost to follow-up and poor health utilization by lung cancer survivors. For instance, McMurry et al. excluded patients who recurred or died in the first 14 months after surgical resection so that they can balance the three surveillance groups (3- vs. 6-month vs. annual) and have complete follow-up data for patients in the three groups. However, a complication of this methodology was that patients who had early recurrence (within 1 year) and would have benefitted most from frequent surveillance were excluded from the analysis. Moreover, lung cancer survivors have the lowest score in health care utilization when compared to long-term survivors of all other cancers (15). Therefore, even if more frequent surveillance detects an early recurrence or second primary, this may not translate into earlier treatment initiation due to poor health care utilization by lung cancer patients. A SEER-Medicare analysis in patients with stage I NSCLC diagnosed between 1998 and 2008 reported that only 61.4% of patients received surveillance in the first 2 years after treatment (16). A number of factors impact health care utilization in lung cancer survivors such as age, geographic location, race/ethnicity and comorbidities (9).

Most studies to date investigating surveillance strategy in lung cancer survivors are retrospective and use data from patients diagnosed before 2010 (9,12,16). Over the last decade, a number of novel therapies have become available for NSCLC treatment. This includes targeted therapy, immunotherapy as well as improved safety and recovery with minimally invasive surgical techniques. A recent meta-analysis reported that robotic lobectomy for the treatment of lung cancer is associated with less complications and lower 30-day mortality compared to open surgery (OR: 0.53; 95% CI: 0.33 to 0.85) (17). With the advent and adoption of these therapeutic advances, survival rates for lung cancer are improving. Even for patients with...
metastatic or stage IV NSCLC, the long-term survival rate has improved from less than 4% to 14% with patients who respond to immunotherapy having a 4-year survival as high as 58% (18). The role of surveillance and associated benefits over the last few years needs to be investigated as patients with earlier identification of recurrence or new primary may have better outcomes due to improved treatment options that are available.

In conclusion, the results from McMurry and colleagues report a lack of benefit from more frequent (at 3 months compared to 6 or 12 months) surveillance in patients treated for early-stage NSCLC with surgical resection. The optimal strategy for surveillance in these survivors has not been clear as studies investigating this to date including the study by McMurry et al. are limited by factors such as retrospective nature, selection bias, and lack of data on patients diagnosed in the last 10 years. Prospective research in this area is warranted as lung cancer continues to be associated with significant morbidity and mortality.

Acknowledgments
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.

References